William Blair Equities Analysts Decrease Earnings Estimates for Tempest Therapeutics, Inc. (NASDAQ:TPST)

Tempest Therapeutics, Inc. (NASDAQ:TPST) – Analysts at William Blair reduced their Q2 2024 EPS estimates for Tempest Therapeutics in a research note issued to investors on Thursday, June 20th. William Blair analyst M. Phipps now anticipates that the company will post earnings per share of ($0.56) for the quarter, down from their previous forecast of ($0.50). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.58) per share. William Blair also issued estimates for Tempest Therapeutics’ Q3 2024 earnings at ($0.45) EPS, Q1 2025 earnings at ($0.53) EPS, Q2 2025 earnings at ($0.62) EPS, Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($2.61) EPS, FY2026 earnings at ($4.09) EPS and FY2027 earnings at ($4.38) EPS.

A number of other equities research analysts also recently commented on the stock. Scotiabank began coverage on shares of Tempest Therapeutics in a research report on Thursday, March 14th. They issued a “sector outperform” rating and a $13.00 target price for the company. Piper Sandler reiterated an “overweight” rating and set a $8.00 price target on shares of Tempest Therapeutics in a research note on Friday. Finally, HC Wainwright reiterated a “buy” rating and set a $47.00 price target on shares of Tempest Therapeutics in a research note on Thursday. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $20.75.

Tempest Therapeutics Trading Up 1.0 %

NASDAQ:TPST opened at $2.03 on Monday. The company has a current ratio of 3.13, a quick ratio of 3.13 and a debt-to-equity ratio of 0.20. Tempest Therapeutics has a 12 month low of $0.17 and a 12 month high of $9.77. The company has a market cap of $45.11 million, a PE ratio of -1.18 and a beta of -1.78. The company has a 50 day simple moving average of $3.24 and a two-hundred day simple moving average of $3.70.

Tempest Therapeutics (NASDAQ:TPST) last posted its earnings results on Thursday, May 9th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.08.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tempest Therapeutics stock. MayTech Global Investments LLC bought a new stake in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 10,000 shares of the company’s stock, valued at approximately $44,000. Tempest Therapeutics makes up approximately 0.0% of MayTech Global Investments LLC’s holdings, making the stock its 29th biggest position. MayTech Global Investments LLC owned approximately 0.05% of Tempest Therapeutics at the end of the most recent quarter. 22.52% of the stock is currently owned by institutional investors.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.